tiprankstipranks
Advertisement
Advertisement

VSTM Stock Latest News

Verastem’s TARGET-D 202 Trial Puts Fresh Focus on KRAS G12D Lung Cancer
Company AnnouncementsVerastem’s TARGET-D 202 Trial Puts Fresh Focus on KRAS G12D Lung Cancer
2d ago
VSTM
Verastem doses first patients in Target-D 203 Phase 2 trial
PremiumThe Fly
Verastem doses first patients in Target-D 203 Phase 2 trial
3d ago
VSTM
Verastem doses first patient in TARGET-D 202 Phase 2 trial
PremiumThe Fly
Verastem doses first patient in TARGET-D 202 Phase 2 trial
9d ago
VSTM
Verastem’s KRAS G12D Trial Targets a New Niche in Colorectal Cancer
PremiumCompany Announcements
Verastem’s KRAS G12D Trial Targets a New Niche in Colorectal Cancer
15d ago
VSTM
Citizens healthcare analysts hold an analyst/industry conference call
PremiumThe Fly
Citizens healthcare analysts hold an analyst/industry conference call
24d ago
CTMX
EXEL
Verastem price target lowered to $14 from $15 at RBC Capital
PremiumThe FlyVerastem price target lowered to $14 from $15 at RBC Capital
25d ago
VSTM
Verastem’s RAMP 204 Trial Completion Signals New Momentum in KRAS G12C Lung Cancer
Premium
Company Announcements
Verastem’s RAMP 204 Trial Completion Signals New Momentum in KRAS G12C Lung Cancer
30d ago
VSTM
Cardiff, Verastem, Fluence, Quantum-Si, Opera Insider Shock
Premium
Weekend Updates
Cardiff, Verastem, Fluence, Quantum-Si, Opera Insider Shock
1M ago
QSI
CRDF
Verastem Advances VS-7375 with Promising Early Trial Data
PremiumCompany Announcements
Verastem Advances VS-7375 with Promising Early Trial Data
1M ago
8K
VSTM
Verastem reports ‘positive’ preliminary data from ongoing TARGET-D trial
PremiumThe Fly
Verastem reports ‘positive’ preliminary data from ongoing TARGET-D trial
1M ago
VSTM
Verastem price target lowered to $8 from $15 at Jefferies
PremiumThe Fly
Verastem price target lowered to $8 from $15 at Jefferies
1M ago
VSTM
Verastem’s KRAS G12D Pancreatic Cancer Trial Advances: What Investors Should Watch
PremiumCompany Announcements
Verastem’s KRAS G12D Pancreatic Cancer Trial Advances: What Investors Should Watch
1M ago
VSTM
Verastem Advances VS-7375 Into Phase 2 Pancreatic Trial
PremiumCompany AnnouncementsVerastem Advances VS-7375 Into Phase 2 Pancreatic Trial
1M ago
8K
VSTM
Verastem announces safety, efficacy results from RAMP 205 Phase 1b/2a study
Premium
The Fly
Verastem announces safety, efficacy results from RAMP 205 Phase 1b/2a study
1M ago
VSTM
Verastem doses first Patient in TARGET-D 201 Phase 2 trial of VS-7375
Premium
The Fly
Verastem doses first Patient in TARGET-D 201 Phase 2 trial of VS-7375
2M ago
VSTM
3 Best Stocks to Buy Today, According to Top Analysts, 6/9/2026
PremiumMarket News
3 Best Stocks to Buy Today, According to Top Analysts, 6/9/2026
2M ago
EVLV
SPTX
Verastem up 11% at $4.00 after announcing FDA Fast Track designation for VS-7375
PremiumThe Fly
Verastem up 11% at $4.00 after announcing FDA Fast Track designation for VS-7375
2M ago
VSTM
Verastem announces FDA Fast Track designation for VS-7375
PremiumThe Fly
Verastem announces FDA Fast Track designation for VS-7375
2M ago
VSTM
Verastem Shareholders Back Board, Executive Pay and Plans
PremiumCompany Announcements
Verastem Shareholders Back Board, Executive Pay and Plans
2M ago
8K
VSTM
Verastem appoints Michael Bailey to board of directors
PremiumThe FlyVerastem appoints Michael Bailey to board of directors
2M ago
VSTM
3 High-Risk, High-Reward Stocks to Buy Now for Explosive Upside, According to Analysts
Premium
Market News
3 High-Risk, High-Reward Stocks to Buy Now for Explosive Upside, According to Analysts
2M ago
WVE
REAX
Verastem price target lowered to $14 from $16 at Mizuho
Premium
The Fly
Verastem price target lowered to $14 from $16 at Mizuho
3M ago
VSTM

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >